Obermatt
See Similar Stocks →

Flags

Financial distress

Adlai Nortye

NMQ:ANL · US00704R1095
BiotechnologySmall

360

17
Profit price92
Owner Earnings Yield1
Dividend Yield1
Price/Sales1
EV / Gross Profit1
Price/Book100
Return on Capital19
Cash Return on Capital7
Profit margins51
Accruals13
Owner Earnings Margin6
Sales growth43
Profit growth1
Reinvestment60
Price momentum100
Debt load1
Refinancing14
Debt Payback1
Liquidity6
Analyst ratings100
Opinion Changes99
Price Target Upside79
Market mood21
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Adlai Nortye doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryCayman Islands
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2018
Websiteadlainortye.com
ISINUS00704R1095
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyOncology

Description

Adlai Nortye Ltd. operates as a global clinical-stage biotechnology company that focuses on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. Leveraging the company’s dual R&D presence in t…

Analysis

Weak and unloved

Adlai Nortye Ltd. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
42
2026

All-time high

42

Jun 2026

All-time low

24

Mar 2026

Average rank

33

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
1
—
—
—
Price/Earnings
100
—
—
—
Price/Book
100
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
64
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Adlai Nortye with its peers
Syngene International
NSI:SYNGENE
78
CountryIndia
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Sun Pharmaceuticals
NSI:SUNPHARMA
55
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Theravance Biopharma
NMQ:TBPH
87
CountryCayman Islands
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Alps Group
NMQ:ALPS
16
CountryMalaysia
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Glenmark Pharmaceuticals
NSI:GLENMARK
58
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Alkem Laboratories
NSI:ALKEM
47
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →